STOCK TITAN

Defence Therapeutics Inc. - DTCFF STOCK NEWS

Welcome to our dedicated page for Defence Therapeutics news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeutics stock.

Defence Therapeutics Inc. (symbol: DTCFF) is a Canadian biopharmaceutical company specializing in immune-oncology therapeutics and drug delivery technologies. The company recently announced the successful development of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an anti-PD-1 immune-checkpoint inhibitor. Defence's unique approach involves the use of reprogrammed mesenchymal stromal cells and AccuTOX® to induce potent antigen presentation for enhanced immune response. The ARM-002TM vaccine is highly versatile and adaptable, being tested on

Rhea-AI Summary

Defence Therapeutics has received a No Objection Letter (NOL) from Health Canada for its Phase I clinical trial of ACCUM-002 (AccuTOX) for treating unresectable Stage IIIB and IV melanoma. The trial, designated ACCUM-002-01, will assess the safety and tolerability of intratumoral administration of AccuTOX, both as a monotherapy and combined with the LAG-3 checkpoint inhibitor relatlimab and PD-1 inhibitor nivolumab (Opdualag). Secondary objectives include collecting preliminary efficacy data and determining the Maximum Tolerated Dose (MTD) and recommended Phase 2 Dose (RP2D). The trial is expected to be conducted in hospitals in Quebec and Ontario. According to Vision Research Reports, the global cancer immunotherapy market is projected to grow significantly, reaching USD 280.11 billion by 2033, with a CAGR of 8.34% from 2024 to 2033.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Defence Therapeutics (CSE: DTC, OTCQB: DTCFF) has announced that its Accum-002™ (AccuTOX®) exhibits dual functionality: acting as a tumor-killing molecule and an immune booster. AccuTOX® works synergistically with Immune Checkpoint Inhibitors (ICI) to enhance the immune system's capability to recognize and attack tumors. This is particularly significant as many solid tumors create a 'cold' environment that impedes immune response, leading to low success rates in ICI treatments. AccuTOX® transforms these cold tumors into 'hot' tumors, significantly increasing the effectiveness of ICIs. Preclinical studies showed a tenfold increase in efficacy when AccuTOX® is combined with various ICIs. Defence is open to partnerships to further develop this promising treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.58%
Tags
none
-
Rhea-AI Summary

Defence Therapeutics has announced that its second-generation ARM-X anti-cancer vaccine, in combination with an anti-PD-1 immune-checkpoint inhibitor, has successfully inhibited the growth of pre-established ovarian cancer in animal models. The study demonstrated complete responses in nearly all treated animals, extending their survival beyond 80 days post-vaccination. This development highlights the versatility of Defence's ARM-X platform, which previously showed effectiveness against solid T-cell lymphoma, melanoma, and pancreatic cancer. The ARM-X vaccine requires lower antigen amounts, making it adaptable to patients' needs regardless of cancer type. The company is also testing ARM-X for colon cancer to set targets for upcoming Phase I-IIa trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Defence Therapeutics' Chief Scientific Officer, Dr. Moutih Rafei, discussed the company's Accum platform for cancer treatments on Money Talk Radio with Ellis Martin. The interview highlighted Defence's innovative approach in the field of immune-oncology, focusing on the enhancement of vaccine efficacy and drug delivery systems. The Accum platform aims to improve the targeting and effectiveness of cancer treatments, potentially transforming the landscape of oncology therapies. The discussion emphasized the platform's potential to make significant advances in cancer treatment.

Listeners can access the full interview on Money Talk Radio's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) is set to participate in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting on June 11, 2024, in Toronto. This event is a key gathering for professionals involved in nuclear and molecular imaging. Defence will showcase AccuTRIC™, a novel Radio-Immuno-Conjugate developed with Orano Support SAS. AccuTRIC™ leverages Defence's AccuTOX® to enhance the treatment of hard-to-treat cancers. The technology aims to improve radiotherapy by using Auger electron emitter elements, which minimize damage to healthy tissues while maximizing therapeutic effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Defence Therapeutics announced the publication of a peer-reviewed study on AccuTOX, an anti-cancer molecule, in the Journal of Translational Medicine. The study details how AccuTOX synergizes with immune-checkpoint inhibitors to disrupt tumor growth. AccuTOX, derived from the Accum platform, shows enhanced killing potency, versatility, and ease of manufacturing. It induces immunogenic cell death and enhances cancer cell visibility to the immune system. The compound targets multiple cancer cell lines and has shown no apparent toxicity in animal models. Defence is initiating a Phase I trial and has submitted a CTA application to Health Canada.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
Rhea-AI Summary

Defence Therapeutics, a biopharmaceutical firm, announced the issuance and allowance of multiple patents across several Patent Families. The US Patent Office allowed application no. 18/169,440, enhancing the company's vaccine platform technology, Accum®, known for boosting antigen presentation. Recent pre-clinical studies using Defence's ARM-002™ vaccine showed significant antitumor responses, paving the way for Phase I trials.

Another patent in Australia for Defence's ADC platform was granted on February 1, 2024, further protecting Accum® and its variants, and adding to existing patents in the US, Japan, and Israel. Additionally, patents for Defence's vaccine platform technology were granted in Canada and Australia, with a Japanese patent expected soon. These patents cover methods and compositions for enhancing antigen immunogenicity.

CEO Mr. Plouffe highlighted the importance of these patents in Defence's mission to innovate and improve human health. The company is accelerating the examination of remaining applications via the Patent Prosecution Highway (PPH) program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Defence Therapeutics Inc. announces successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer, showing therapeutic effectiveness when combined with an immune-checkpoint inhibitor. Results reveal potent vaccine efficacy with tumor growth inhibition, positioning the company to target 'hard-to-treat' cancers like pancreatic cancer. The pancreatic cancer market is projected to exceed USD 36 billion by 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
Rhea-AI Summary
Defence Therapeutics Inc. announces the success of its second-generation ARMTM anti-cancer vaccine, ARM-002TM, which has shown therapeutic effectiveness against pre-established melanoma when combined with an immune-checkpoint inhibitor. The vaccine utilizes AccuTOX® to induce protein aggregation in mesenchymal stromal cells, leading to potent antigen presentation. ARM-002TM is more potent than its predecessor, requiring 10x less protein for similar outcomes in both in vitro and in vivo studies. The vaccine is being tested on 'hard-to-treat' cancers like pancreatic, colon, and ovarian cancers, showing promising versatility and adaptability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Defence Therapeutics partners with FMS Consult GmbH for financing strategy to support pipeline growth. The company's Accum® platform shows promise in cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Defence Therapeutics Inc.

OTC:DTCFF

DTCFF Rankings

DTCFF Stock Data

28.47M
43.01M
4.74%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Vancouver